Key takeaways
- Founded in 2005 in Visakhapatnam, focused first on anti-retroviral (ARV) APIs for HIV treatment.
- It became one of the world’s largest ARV API producers and listed in December 2016.
- It diversified into oncology, cardiovascular APIs, a CDMO arm and, from 2021, biologics.
- By FY25 revenue topped ₹5,000 crore as CDMO and biologics reduced its ARV concentration.
- 2005 Dr. Satyanarayana Chava founds Laurus Labs in Visakhapatnam, focused first on anti-retroviral (ARV) APIs for HIV treatments.
- 2010 It becomes one of the world’s largest ARV API producers.
- Dec 2016 Laurus Labs lists at ₹428.
- 2019 It diversifies into oncology and cardiovascular APIs and adds a custom-synthesis CDMO arm.
- 2021 A biologics platform begins, and the stock compounds rapidly through COVID as oncology and CDMO revenue scale.
- 2023 The ARV cycle softens as global treatment guidelines change, and the stock corrects from its highs.
- 2024 First biologics revenue arrives and the custom-synthesis order book scales.
- FY25 Revenue tops ₹5,000 crore, profit recovers from FY24 lows, and the CDMO share of revenue keeps expanding.
- 2025 Diversification away from ARV concentration shows in the revenue mix, a new biologics facility at Visakhapatnam is commissioned, and CDMO and biologics are flagged as the primary growth drivers.
- 2026 The biologics platform scales, CDMO grows, and ARV stabilises at a smaller share of revenue.
Laurus Labs carries one of the strongest scientific platforms in Indian pharma. Anti-retroviral APIs were the first chapter; CDMO, biologics and custom synthesis are the next three, and the stock cycles around the visibility of each transition. Here is the journey, year by year.
The pattern is the point
Laurus has one of the strongest science platforms in Indian pharma: ARV was the first chapter, and CDMO, biologics and synthesis are the next three. The compounders are the ones that earn the right to a second chapter on the back of the first, and the share price tends to move with the market’s confidence in each new transition.
